SIGH35与呼气末闭塞试验评估压力支持通气危重患者容量反应性
该前瞻性研究在综合ICU纳入56例压力支持通气且需容量扩张的患者,比较SIGH35(35 cmH2O持续4秒的呼吸机叹气)与呼气末闭塞试验预测容量反应性的可靠性。容量反应性定义为10分钟内输注4 ml/kg晶体液后心输出量(CO)≥10%。SIGH35的脉压变化AUC为0.93,优于呼气末闭塞试验CO变化的AUC 0.67;在P0.1<1.5 cmH2O亚组中两者AUC相当(p=0.26)。
要点
- 在压力支持通气患者中,SIGH35脉压变化预测容量反应性的AUC为0.93(95%CI 0.84-0.99),最佳阈值为脉压较基线下降25%。
- 呼气末闭塞试验CO变化的AUC为0.67(95%CI 0.52-0.81),最佳阈值为CO较基线增加4%。
- SIGH35的AUC显著大于呼气末闭塞试验(原文报告AUC比较),诊断可靠性更高。
- 在P0.1<1.5 cmH2O亚组中,SIGH35与呼气末闭塞试验的AUC分别为0.98和0.89,两者相当(p=0.26)。
- SIGH35操作:呼吸机给予35 cmH2O持续4秒的叹气,记录脉压最低值;呼气末闭塞试验记录试验结束时CO变化百分比。
适用人群与场景
- 综合ICU中接受压力支持通气(PSV)且需要容量扩张(VE)的危重患者。
- 研究纳入具有不同吸气努力程度(通过气道闭合压P0.1评估)的压力支持通气患者。
诊断标准与关键阈值
- 容量反应性定义:10分钟内输注4 ml/kg晶体液后心输出量(CO)较基线增加≥10%。
- SIGH35最佳阈值:脉压较基线下降25%(灰色区域15%-35%)。
- 呼气末闭塞试验最佳阈值:CO较基线增加4%(灰色区域1%-10%)。
处置流程与药物剂量
- SIGH35操作:呼吸机给予35 cmH2O持续4秒的叹气,记录脉压(PP)较基线至SIGH35后最低值的变化百分比。
- 呼气末闭塞试验操作:记录基线至试验结束时CO的变化百分比。
- 容量扩张方法:10分钟内输注4 ml/kg晶体液。
研究设计与关键结果
- 研究类型:前瞻性研究;样本量:纳入60例ICU患者,最终分析56例。
- SIGH35脉压变化的AUC为0.93(95%CI 0.84-0.99),敏感性93.1%(95%CI 78.0-98.7%),特异性91.6%(95%CI 73.0-98.9%)。
- 呼气末闭塞试验CO变化的AUC为0.67(95%CI 0.52-0.81),敏感性72.4%(95%CI 54.3-85.3%),特异性70.3%(原文写作73.0-98.9%,此处表述有矛盾)。
- SIGH35的AUC大于呼气末闭塞试验的AUC。
- 在P0.1<1.5 cmH2O亚组中,SIGH35的AUC为0.98(95%CI 0.94-0.99),呼气末闭塞试验的AUC为0.89(95%CI 0.72-0.99),两者比较p=0.26。
证据类型、等级与局限
- 证据类型:前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在压力支持通气患者中,SIGH35可较可靠地预测容量反应性,且表现优于呼气末闭塞试验。
- 对于P0.1<1.5 cmH2O(吸气努力较小)的患者,呼气末闭塞试验仍可靠,与SIGH35预测能力相当。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Assessing fluid responsiveness is problematic for critically ill patients with spontaneous breathing activity, such as during Pressure Support Ventilation (PSV), since spontaneous breathing activity physiologically affects heart-lung interplay. We compared the reliability of two hemodynamic tests in predicting fluid responsiveness in this clinical setting: SIGH35, based on a ventilator-generated sigh applied at 35 cmH2O for 4 s and the end-expiratory occlusion test (EEOT).
METHODS: Prospective study conducted in a general intensive care unit (ICU) and enrolling patients in PSV showing different inspiratory effort [assessed by airway occlusion pressure (P0.1)] and requiring volume expansion (VE). Hemodynamic variables were recorded by means of the MOSTCARE® system, patient received a VE using 4 ml/kg of crystalloids over 10 min and were considered responders if a cardiac output (CO) ≥ 10% was observed. The reliability of SIGH35 and EEOT in discriminating fluid responsiveness was assessed using receiver operating characteristic (ROC) curve approach and the area (AUC) under ROC curves was compared. For the EEOT, we considered the percent changes of CO between baseline the end of the test, while for the SIGH35, the percent changes of pulse pressure (PP) between baseline and the lowest value recorded after SIGH35 application.
RESULTS: Sixty ICU patients were enrolled, and 56 patients analysed. The AUC of PP changes after SIGH35 was 0.93 (0.84-0.99) [sensitivity of 93.1% (78.0-98.7%); specificity of 91.6 (73.0-98.9%)]; best threshold - 25% PP from baseline (grey zone - 15%/35%)]; and greater than the AUC of CO changes after EEOT [0.67 (0.52-0.81); sensitivity of 72.4% (54.3-85.3%) specificity of 70.3% (73.0-98.9%)]; best threshold 4% of CO increase from baseline (grey zone - 1%/10%)]. In the subgroup having a P0.1 < 1.5 cmH2O, the AUC of SIGH35 [0.98 (0.94-0.99)] and of EEOT [0.89 (0.72-0.99] were comparable (p = 0.26).
CONCLUSIONS: In a selected ICU population undergoing PSV, SGH35 reliably predicted fluid responsiveness and performed better than the EEOT, which is, however, still reliable in the subgroup of ICU patients having a small extent of inspiratory efforts.
参考来源
- Messina A, Calabrò L, Benedetto F, et al. SIGH35 and end-expiratory occlusion test for assessing fluid responsiveness in critically ill patients undergoing pressure support ventilation. Crit Care. 2025. PMID: 40317039. doi:10.1186/s13054-025-05398-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。